Education
About Us
Working with TipRanks
Follow Us
NervGen Pharma (NGENF)
OTHER OTC:NGENF
NGENF Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.46 - $5.10
Previous CloseN/A
Volume22.02K
Average Volume (3M)87.10K
Market Cap
$200.67M
Enterprise Value$231.86M
Total Cash (Recent Filing)$15.73M
Total Debt (Recent Filing)$57.71K
Price to Earnings (P/E)―
Beta0.21
Next Earnings
Nov 13, 2025EPS Estimate
-0.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.09
Shares Outstanding73,277,290
10 Day Avg. Volume78,104
30 Day Avg. Volume87,099
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap1.16
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-8.31K
Enterprise Value/Ebitda-8.78
Forecast
1Y Price Target
$7.40Price Target Upside177.15% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
NervGen Pharma News
NGENF FAQ
What was NervGen Pharma’s price range in the past 12 months?
NervGen Pharma lowest stock price was $1.46 and its highest was $5.10 in the past 12 months.
What is NervGen Pharma’s market cap?
NervGen Pharma’s market cap is $200.67M.
When is NervGen Pharma’s upcoming earnings report date?
NervGen Pharma’s upcoming earnings report date is Nov 13, 2025 which is in 64 days.
How were NervGen Pharma’s earnings last quarter?
NervGen Pharma released its earnings results on Aug 26, 2025. The company reported -$0.094 earnings per share for the quarter, missing the consensus estimate of -$0.054 by -$0.04.
Is NervGen Pharma overvalued?
According to Wall Street analysts NervGen Pharma’s price is currently Undervalued.
Does NervGen Pharma pay dividends?
NervGen Pharma does not currently pay dividends.
What is NervGen Pharma’s EPS estimate?
NervGen Pharma’s EPS estimate is -0.05.
How many shares outstanding does NervGen Pharma have?
NervGen Pharma has 73,277,290 shares outstanding.
What happened to NervGen Pharma’s price movement after its last earnings report?
NervGen Pharma reported an EPS of -$0.094 in its last earnings report, missing expectations of -$0.054. Following the earnings report the stock price went down -3.788%.
Which hedge fund is a major shareholder of NervGen Pharma?
Currently, no hedge funds are holding shares in NGENF
NervGen Pharma Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$7.40 (177.15% Upside)
$7.40 (177.15% Upside)
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
37.62%
12-Months-Change
Fundamentals
Return on Equity
-457.00%
Trailing 12-Months
Asset Growth
-39.15%
Trailing 12-Months
Company Description
NervGen Pharma
NervGen Pharma Corp., together with its subsidiaries, engages in the discovery, development, and commercialization of pharmaceutical treatments for medical conditions related to nervous system damage. Its lead product candidate is NVG-291 that is in phase 1 clinical trial for the treatment of spinal cord injuries (SCI), multiple sclerosis, and Alzheimer's disease. The company has a licensing agreement with Case Western Reserve University to research, develop, and commercialize a patented technology with therapeutic potential for SCI and other conditions associated with nerve damage. NervGen Pharma Corp. was incorporated in 2017 and is based in Vancouver, Canada.
NGENF Stock 12 Month Forecast
Average Price Target
$7.40
▲(177.15% Upside)
Technical Analysis
Satellos Bioscience
―
Arch Biopartners
―
Fennec Pharmaceuticals
―
Bright Minds Biosciences
―
Eupraxia Pharmaceuticals
―
Ownership Overview
15.76% Insiders
<0.01% Other Institutional Investors
84.24% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---